Markets:

Overview

News

Currencies

International

Treasuries

AbCellera Biologics Inc. - Common Shares (NQ:ABCL)

6.015 +0.215 (+3.71%)

Streaming Delayed Price Updated: 1:10 PM EDT, Jul 21, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about AbCellera Biologics Inc. - Common Shares

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

A $50B AI Drug Discovery Revolution Has Begun - Here Are 6 Stocks To Consider Investing In ↗

May 20, 2024

The drug development process is very expensive and time-consuming which creates a huge shortage in drug candidates and programs but the advent of AI can significantly shorten and cheapen this process...

Via Talk Markets

Topics Artificial Intelligence

Largest Clinical-Stage BioTech Drug Stocks Declined 3% Last Week ↗

May 13, 2024

Via Talk Markets

3 Stock Gems Hiding in the Nasdaq ↗

May 13, 2024

If you don’t mind taking a risk in the discount section, these undervalued Nasdaq stocks just might surprise some folks.

Via InvestorPlace

5 Of 7 AI Categories Rose, Slightly,Over Past Week ↗

May 11, 2024

The 7 AI categories we track went up marginally (1.0%, on average) the second week of May, after having gone down 0.4% the previous week.

Via Talk Markets

Topics Artificial Intelligence

AbCellera Biologics (ABCL) Q1 2024 Earnings Call Transcript ↗

May 08, 2024

ABCL earnings call for the period ending March 31, 2024.

Via The Motley Fool

Topics Earnings

Recap: AbCellera Biologics Q4 Earnings ↗

February 20, 2024

Via Benzinga

ABCL Stock Earnings: AbCellera Biologics Beats EPS, Misses Revenue for Q1 2024 ↗

May 07, 2024

ABCL stock results show that AbCellera Biologics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.

Via InvestorPlace

AbCellera Reports Q1 2024 Business Results

May 07, 2024

From AbCellera Biologics Inc.

Via Business Wire

Clinical-Stage BioTech Drug Stocks Portfolio Jumped 7% In First Week Of May ↗

May 05, 2024

We look at the performance of 10 clinical-stage AI-powered and psychedelic compound-based small cap drug discovery companies during the first week of May and YTD.

Via Talk Markets

AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies

May 01, 2024

From AbCellera Biologics Inc.

Via Business Wire

Clinical-Stage BioTech Drug Stocks Portfolio Went Down 9% Last Week ↗

April 23, 2024

A look at the 10 clinical-stage AI-powered and psychedelic compound-based small-cap drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio, their stock performances last week and...

Via Talk Markets

The 10 Stocks In The Clinical-Stage BioTech Drug Stocks Index Are Down 4% YTD ↗

April 15, 2024

The pharmaceutical industry is embracing AI to streamline drug discovery and researching the use of psychedelic compound-based ingredients for the treatment of, as yet, untreatable diseases.

Via Talk Markets

Topics Artificial Intelligence

AbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024

April 08, 2024

From AbCellera Biologics Inc.

Via Business Wire

AbCellera to Report First Quarter 2024 Financial Results on May 7, 2024

April 03, 2024

From AbCellera Biologics Inc.

Via Business Wire

The 7 Best Penny Stocks to Buy in Q2 2024 ↗

March 27, 2024

Discover seven penny stocks to buy primed for significant gains in Q2 2024. Don't miss out on these picks or your portfolio could suffer.

Via InvestorPlace

AbCellera to Present at the Bloom Burton Healthcare Conference on April 16, 2024

March 19, 2024

From AbCellera Biologics Inc.

Via Business Wire

AbCellera to Collaborate with Biogen to Discover Therapeutic Antibodies for Neurological Conditions

March 11, 2024

From AbCellera Biologics Inc.

Via Business Wire

Recap: These 7 Artificial Intelligence (AI) Stock Categories Had Returns From +2 To +15% In February ↗

March 06, 2024

This article is a recap of how 7 artificial intelligence stock categories did in February, and YTD, compared to each other to help you make prudent investment decisions accordingly.

Via Talk Markets

Topics Artificial Intelligence

AbCellera Announces Four Presentations on T-Cell Engagers at AACR 2024

March 05, 2024

From AbCellera Biologics Inc.

Via Business Wire

AI-Powered Drug Discovery Stocks Index Up 9% In February; Remains Down 8% YTD ↗

March 04, 2024

Grand View Research says the global

Via Talk Markets

3 Highly Rated Biotech Stocks to Buy for 300% Gains ↗

February 26, 2024

Biotech stocks like those discussed here have the potential to produce 300% returns and benefit from high analyst ratings.

Via InvestorPlace

AbCellera Announces Resignation of Board Member

February 23, 2024

From AbCellera Biologics Inc.

Via Business Wire

AbCellera to Present at Upcoming Investor Conferences in March

February 22, 2024

From AbCellera Biologics Inc.

Via Business Wire

AbCellera Biologics (ABCL) Q4 2023 Earnings Call Transcript ↗

February 20, 2024

ABCL earnings call for the period ending December 31, 2023.

Via The Motley Fool

Topics Earnings

AbCellera Reports Full Year 2023 Business Results

February 20, 2024

From AbCellera Biologics Inc.

Via Business Wire

Earnings Scheduled For February 20, 2024 ↗

February 20, 2024

Companies Reporting Before The Bell • Barclays (NYSE:BCS) is likely to report quarterly earnings at $0.36 per share on revenue of $7.38 billion.

Via Benzinga

These 9 AI Stock Categories Performed From +18% To -4% Last Week ↗

February 19, 2024

A synopsis of the performances of each of the 9 different artificial intelligence stock categories last week, and YTD, along with a description of what makes up each category and the stocks included in...

Via Talk Markets

Topics Artificial Intelligence

AI-Powered Drug Discovery Stocks Index Up 18% Last Week, Led By BioXcel Therapeutics ↗

February 19, 2024

The AI-powered drug discovery market is projected to grow at a 30% CAGR between now and 2030, with annual sales in excess of $50 billion anticipated. An AI drug discovery revolution is underway.

Via Talk Markets

Topics Artificial Intelligence

AbCellera to Report Full Year 2023 Financial Results on February 20, 2024

January 23, 2024

From AbCellera Biologics Inc.

Via Business Wire

4 Magnificent Healthcare Stocks to Buy in 2024 and Beyond ↗

January 16, 2024

Healthcare stocks have underperformed in 2023, but that is expected to change this year.

Via The Motley Fool

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.